Reitz et al. reported that a combination of CEA and CA19-9 compared to CEA or CA19-9 alone improved the prognostic prediction in OS of stage I-III pancreatic cancer patients [44]. This evidence concerns the gene CEACAM5 and familial pancreatic carcinoma.